Europe also, I mean, we see a lot of science work in Europe. So, I would think that we’ll — in Europe, we’ll focus a little bit more on the science side. And then, with the U.S. and China, they’re actual more higher-volume commercial applications and again, high-volume type of operations.
Frank DiLorenzo: Okay. Thanks. Just kind of a quick follow-on. You did talk quite a bit about some of the new product launches that have been going on. Is there any potential later in this year into 2025 for some additional new product introductions or line extensions? And also, somewhat related to that, what is the landscape look like out there for potentially maybe some partnerships or small sort of M&A activity to kind of bolster some of your current future offerings? Thanks. That’s it.
Jim Green: Yeah. Good question. Let’s talk about — the partnership thing is certainly, there’s no question, there’s a lot of companies that would really like to penetrate some of the things like areas like bioproduction. There’re companies that really want to see — are interested in some of these technologies that might be used even in clinical applications. So, there are areas there that we could look — that we will be looking to potentially license out, and that would be in areas that where we’re not — where we really don’t have the capacity or the funding to be able to go after all of it. So, to me, the focus is going to be if you look at those core growth areas, that’s where as we develop new products, we’ll continue to do that, they will fit primarily into those four focus areas.
And hopefully, again, like I said, the things that I can’t do with a company our size, but I can do if I leverage some other major players that really heavily want to be in some of these areas that I can look to license some of what we’re doing through them. And again, I may as well create the value if I can’t get it directly. I’m happy to get it through working with some partners. And your thoughts about acquisitions, we now are at the point where I think we have the — we have capital structure in place. As we start to think about acquisitions, there are areas that are very interesting that could fit nicely into our product portfolio. And some of these areas are certainly — bioproduction provides some areas that we could potentially augment some of our portfolio.
And then, expanding and accelerating what we’re doing with the cellular work with organoids, that could be interesting. And a number of our products — as you know, in the past, there was not a lot of recurring revenue with some of these products. You see the new ones we’re doing, they’re designed specifically to bring in recurring revenue, to have consumables, to have services and field services. We’re going to continue to explore and ramp those up. And that’s an area that we have some interest potentially for acquisition. When you think about some of the consumables and buffers and things that are provided — that are needed by our — that our products consume in order to provide the function for their customers. So, there’s a plethora of items for us to expand here.
We do have — again, we’re not that big, so we have to be selective of where we make that investment. But it’s nice to be in a position where you have a wide area that you could do. But again, we’re going to focus on the areas that are going to give us that pricing power and keep us — and the ability to stay in our niches and expand from there.
Frank DiLorenzo: Okay. Thank you.
Jim Green: Thanks, Frank.
Operator: Thank you. And there are no further questions in the queue at this time. I will now turn the call back over to Mr. Jim Green for any closing remarks.
Jim Green: Okay. Well, thank you, everybody. Thank you for listening in today. This ends today’s presentation. I hope that you’ll join us in May for our first quarter results of fiscal 2024. Thank you very much. This ends the presentation.
Operator: Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation. You may now disconnect.
